Skip to main content
All lobbying clients

Uniqure Biopharma B.V.

Uniqure Biopharma B.V. has been represented by 1 lobbying firm in 5 filings since 2025, with $250,000 in reported spending; the newest was posted October 20, 2026.

As filed: UNIQURE BIOPHARMA B.V.

biopharma

$250,000 Reported spend
5 Filings counted
1 Outside firm hired
0 Bills named

Spend is reported income plus in-house expenses across 5 filings. Everything on this page comes from one LDA client record (70535), filed by the registrant listed below.

 Who filed for this client 1

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Reported by year 2 years
  • 2026 $240,000 3 filings
  • 2025 $10,000 2 filings
 Issues lobbied 1

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 3
  • Food & Drug Administration (FDA) 4
  • HOUSE OF REPRESENTATIVES 4
  • SENATE 4
 Recent filings 5 total
Q3 report
Tarplin, Downs & Young, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 20, 2026
View → Q2 report
Tarplin, Downs & Young, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 20, 2026
View → Q1 report
Tarplin, Downs & Young, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $80,000 income · posted Apr 20, 2026
View → Q4 report
Tarplin, Downs & Young, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $10,000 income · posted Jan 20, 2026
View → Registration
Tarplin, Downs & Young, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · posted Jan 13, 2026
View →

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem